lifestyle.hoteleguide.com

Author: Shanghai EpimAb Biotherapeutics Co., Ltd.

EpimAb Biotherapeutics to Present a Novel Prodrug T-Cell Engager (ProTCE) Platform at the 2026 American Association for Cancer Research Annual Meeting

April 14, 2026
EpimAb Biotherapeutics Announces the First CTA Filing of a FIT-IG® Bispecific Antibody by its License Partner Almirall

February 12, 2026